
Product Data Sheet

Product Name: Dorsomorphin (Compound C) 2HCl

Cat. No.: GC12560

Chemical Properties

Cas. No. 1219168-18-9

Chemical Name 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine; dihydrochloride

SMILES C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3.Cl.ClFormula $C_{24}H_{25}N_5O \cdot 2HCl$

M.Wt 472.41

Solubility $\geq 100\text{mg/mL}$ in Water, $\geq 5.9\text{mg/mL}$ in DMSO, $\geq 11.34\text{ mg/mL}$ in 0.9% NSStore at -
Storage 20°C , protect from
lightGeneral tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure **Protocol****Kinase
experiment****[1]:**

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

AMPK partial
purification and
in vitro kinase
assay

Liver AMPK is partially purified from male SD rats to the blue-Sepharose step. The 100- μ l reaction mixture contains 100 μ M AMP, 100 μ M ATP (0.5 μ Ci 33P-ATP per reaction), and 50 μ M SAMS in a buffer (40 mM HEPES, pH 7.0, 80 mM NaCl, 0.8 mM EDTA, 5 mM MgCl₂, 0.025% BSA, and 0.8 mM DTT). The reaction is initiated with addition of the enzyme. After 30-minute incubation at 30°C, the reaction is stopped by addition of 80 μ l 1% H₃PO₄. Aliquots (100 μ l) are transferred to 96-well MultiScreen plates. The plate is washed three times with 1% H₃PO₄ followed by detection in a Top-count. The in vitro AMPK inhibition data obtained with compound C — (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-4-yl-pyrazolo[1,5-a] pyrimidine — are fit to the following equation for competitive inhibition by nonlinear regression using a least-squares Marquardt algorithm in a computer program written by N. Thornberry of Merck Research Laboratories: $V_i/V_o = (K_m + S)/[S + K_m \times (1 + I/K_i)]$, where V_i is the inhibited velocity, V_o is the initial velocity, S is the substrate (ATP) concentration, K_m is the Michaelis constant for ATP, I is the inhibitor (compound C) concentration, and K_i is the dissociation constant for compound C.

**Cell
experiment
[2]:**

Cell lines mouse pulmonary artery smooth muscle cells (PASMCs), Hep3B cells

Preparation method The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reacting condition 0.1-20 μ M for 30 min

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Applications Dorsomorphin (4 μ M) inhibited osteogenic differentiation in C2C12 cells and suppressed BMP-mediated SMAD activation by blocking BMP type I receptor function. Moreover, treatment with dorsomorphin (1 μ M) blocked BMP- and HJV-mediated hepcidin expression in cultured hepatoma-derived cells.

Animal experiment [2]:

Animal models Zebrafish embryos model; Wild-type (WT) C57BL/6 adult mice model

Dosage form 10 mM dorsomorphin for 30 h; or 10 mg/ kg, intraperitoneal injection

Applications Dorsomorphin induced dorsalization in zebrafish embryos model. Moreover, Dorsomorphin inhibited bone mineralization in vivo. Additionally, Dorsomorphin (10 mg/ kg) induced hyperferremia in mice.

Other notes Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J. and Moller, D.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108, 1167-1174

2. Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., Lin, H. Y., Bloch, K. D. and Peterson, R. T. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 4, 33-41

Background

IC50: Dorsomorphin inhibited BMP4-induced phosphorylation of BMP-responsive SMADs in a dose-dependent manner (half maximal inhibitory concentration (IC50) =0.47 mM). Bone morphogenetic protein (BMP) signals coordinate developmental patterning and have essential physiological roles in mature organisms. The first known small-molecule inhibitor of BMP signaling, dorsomorphin, were identified in a screen for compounds that perturb dorsoventral axis formation in zebrafish.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In vitro: Previous researchers found that dorsomorphin selectively inhibits the BMP type I receptors ALK2/ALK3/ALK6 leading to block BMP-mediated SMAD1/5/8 phosphorylation, osteogenic differentiation as well as target gene transcription. Using dorsomorphin, they examined the role of BMP signaling in iron homeostasis. Dorsomorphin inhibited the systemic iron regulator hepcidin BMP-, hemojuvelin- and interleukin 6-stimulated expression, indicating that BMP receptors regulate hepcidin induction by all of these stimuli [1].

In vivo: The systemic challenge with iron rapidly induced SMAD1/5/8 phosphorylation and hepcidin expression in the liver, while dorsomorphin treatment could block SMAD1/5/8 phosphorylation, normalize hepcidin expression and increase serum iron levels. These suggest an crucial physiological role for hepatic BMP signaling in iron-hepcidin homeostasis [1].

Clinical trial: Dorsomorphin is still in preclinical development stage and no clinical trial is ongoing currently.

Reference:

[1] Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. *Nat Chem Biol.* 2008;4(1):33-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA